Nerad v. Astrazeneca Pharmaceuticals, Inc.Nerad v. Astrazeneca Pharmaceuticals, Inc.
III. CONCLUSION
For these reasons, we AFFIRM the district court‘s decision dismissing Brown‘s civil rights action without prejudice. Further, we remind Brown of his continuing obligation to make partial payments until the full amount of his appellate filing fee is paid.
Terry W. West, Shawnee, OK, Brandon Duane Watkins, The West Law Firm, Shawnee, OK, Bradley C. West, West Law Firm, Shawnee, OK, for Plaintiff-Appellee.
Paul J. Zidlicky, Eamon P. Joyce, Rebecca K. Wood, Sidley, Austin, Brown & Wood, Washington, DC, Thomas G. Wolfe, Raymond E. Zschiesche, Phillips, McFall, McCaffrey, McVay & Murrah, Oklahoma City, OK, James W. Mizgala, Michael W. Davis, Sidley Austin Brown & Wood, Chicago, IL, for Defendants-Appellants.
Before KELLY, HOLLOWAY, and McCONNELL, Circuit Judges.*
ORDER AND JUDGMENT **
PAUL KELLY, JR., Circuit Judge.
Defendant AstraZeneca Pharmaceuticals, Inc., appeals from the district court‘s* After examining the briefs and the appellate record, this three-judge panel has determined unanimously that oral argument would not be of material assistance in the determination of this appeal. See
** This order and judgment is not binding precedent, except under the doctrines of law of
Background
On November 15, 2004, Plaintiff Ron Nerad filed a complaint in Oklahoma state court alleging products liability, fraud and misrepresentation claims against Defendant AstraZeneca and its drug sales representative, Defendant Timothy Sydnes. These claims arose from injuries Mr. Nerad allegedly received from using the drug Crestor.
AstraZeneca removed the matter to federal court. Mr. Nerad promptly moved for remand, asserting without dispute that both he and Mr. Sydnes were citizens of Oklahoma. AstraZeneca maintained that Mr. Sydnes had been fraudulently joined, and it opposed the remand on the ground that the only proper parties to the action—itself and Mr. Nerad—were diverse.
On March 11, 2005, the district court granted Mr. Nerad‘s motion for remand. Aplt. App. at 49-53. In a ruling not contested in this appeal, the district court held that Mr. Sydnes was fraudulently joined to the products liability claim. However, it also determined that Mr. Sydnes was properly joined to the fraud and misrepresentation claims. AstraZeneca argued that Mr. Nerad failed to plead those claims with sufficient particularity to satisfy
Based on these rulings, the court concluded that AstraZeneca had failed to carry its “heavy” burden of demonstrating fraudulent joinder. Thus, the court held that it lacked subject matter jurisdiction because Mr. Nerad and Mr. Sydnes were not diverse, and it remanded the case to state court. This appeal followed.
Discussion
The threshold question we must answer is whether this court is permitted to review the district court‘s remand order. Under
Accordingly, this court can review a remand order only if it had a basis outside of
The district court held that regardless of whether the pleadings were technically deficient under
The allegations of fraudulent joinder complicate our analysis. While a court normally evaluates the propriety of a removal by determining whether the allegations on the face of the complaint satisfy the jurisdictional requirements, fraudulent joinder claims are assertions that the pleadings are deceptive. Thus, in cases where fraudulent joinder is claimed, we have directed courts to “pierce the pleadings, consider the entire record, and determine the basis of joinder by any means available.” Dodd v. Fawcett Publ‘ns, Inc., 329 F.2d 82, 85 (10th Cir.1964) (citations omitted). In so doing, the court must decide whether there is a reasonable basis to believe the plaintiff might succeed in at least one claim against the non-diverse defendant. See Badon v. RJR Nabisco, Inc., 224 F.3d 382, 393 (5th Cir.2000). A “reasonable basis” means just that: the claim need not be a sure-thing, but it must have a basis in the alleged facts and the applicable law.
We have previously indicated that “a fraudulent joinder analysis [is] a jurisdictional inquiry.” Albert v. Smith‘s Food & Drug Ctrs., Inc., 356 F.3d 1242, 1247 (10th Cir.2004). Although we have not addressed the question in the context of whether a remand order based on a finding of fraudulent joinder is reviewable, our sister circuits agree that such orders are not reviewable. As the Fifth Circuit explained:
The district court ruled on an argument put before it that directly implicated the subject matter jurisdiction of that court. The court explicitly held “that the joinder of the tribe is not fraudulent, and that the stateless status of the tribe therefore destroys complete diversity, and along with it, this Court‘s diversity jurisdiction.” The accompanying remand falls directly within § 1447(c). Consequently, pursuant to § 1447(d), we lack jurisdiction to review the order of remand.
Victor v. Grand Casino-Coushatta, 359 F.3d 782, 784-85 (5th Cir.2004) (per curiam); see also Hernandez v. Seminole County, 334 F.3d 1233 (11th Cir.2003); Garbie v. DaimlerChrysler Corp., 211 F.3d 407 (7th Cir.2000).
This rationale is consistent with Dalrymple, where we considered whether we could review a remand order premised on a lack of federal question jurisdiction. The plaintiffs had brought a class-action lawsuit against a state agency, which removed the case to federal court based on
The remand orders at issue clearly do not reflect the typical nonjurisdictional determination involving a discretionary remand of supplementary or pendent claims, venue, abstention, comity, or the waiver of opportunity to challenge a procedurally irregular removal. Instead, the orders address key issues directly related to whether the district court could have exercised subject matter jurisdiction over the cases—the presence of a federal question on the face of the plaintiffs’ complaints, and/or the presence of a federal question in the form of a colorable federal immunity defense.
Likewise, the order in this case addressed key issues related to whether the district court had subject-matter jurisdiction. The pleadings on their face reflected a lack of complete diversity. In the hope of convincing the court that it had jurisdiction, AstraZeneca invited it to “pierce the pleadings, consider the entire record, and determine the basis of joinder by any means available.” Dodd, 329 F.2d at 85 (internal citations omitted). Although the court considered whether future amendments might allow Mr. Nerad to state his claims with sufficient particularity to satisfy
Therefore, we conclude that the district court remanded based on its conclusion that it lacked subject-matter jurisdiction at the time of removal. The remand was thus ordered pursuant to